Original Article
Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes
N Engl J Med 2004; 350:11-20January 1, 2004
- Abstract
Background
Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV.
Methods
We followed 1484 immunocompetent, heterosexual, monogamous couples: one with clinically symptomatic genital HSV-2 and one susceptible to HSV-2. The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months. The susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes. Source partners were followed for recurrences of genital herpes; 89 were enrolled in a substudy of HSV-2 mucosal shedding. Both partners were counseled on safer sex and were offered condoms at each visit. The predefined primary end point was the reduction in transmission of symptomatic genital herpes.
Results
Clinically symptomatic HSV-2 infection developed in 4 of 743 susceptible partners who were given valacyclovir, as compared with 16 of 741 who were given placebo (hazard ratio, 0.25; 95 percent confidence interval, 0.08 to 0.75; P=0.008). Overall, acquisition of HSV-2 was observed in 14 of the susceptible partners who received valacyclovir (1.9 percent), as compared with 27 (3.6 percent) who received placebo (hazard ratio, 0.52; 95 percent confidence interval, 0.27 to 0.99; P=0.04). HSV DNA was detected in samples of genital secretions on 2.9 percent of the days among the HSV-2–infected (source) partners who received valacyclovir, as compared with 10.8 percent of the days among those who received placebo (P<0.001). The mean rates of recurrence were 0.11 per month and 0.40 per month, respectively (P<0.001).
Conclusions
Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2–discordant couples.
Media in This Article
Figure 1
Kaplan–Meier Plots of Time to Acquisition of HSV Infection among Susceptible Sexual Partners of Persons with Genital HSV-2 Infection, According to the Source Partner's Treatment Group.Figure 2
Frequency and Titer of HSV-2 Shedding among Valacyclovir-Treated as Compared with Placebo-Treated Source Partners.Article Activity
- Article
Herpes simplex virus type 2 (HSV-2) causes a chronic genital viral infection characterized by high rates of clinical and subclinical reactivation in the genital mucosa and the attendant risk of sexual transmission.1-4 Both symptomatic and asymptomatic reactivations of HSV infection have been shown to result in sexual transmission.5-8 Population-based studies in the United States indicate that 22 percent of adults have antibodies to HSV-2 and that an estimated 1.6 million new cases of HSV-2 infection are acquired yearly.9,10 HSV-2 has become the most frequent cause of genital ulcer disease in all regions of the world.11-14
Transmission of genital herpes to others is the chief concern in persons with known genital herpes.15-17 Although antiviral agents have been shown for nearly two decades to reduce the frequency of clinical reactivation of genital herpes,18,19 only more recently has it been shown that daily antiviral therapy also reduces the frequency and amount of HSV that is shed subclinically on genital mucosal surfaces, the principal source of transmitted infections.20-22 This reduction in subclinical shedding provided the rationale for our randomized, placebo-controlled trial, which was designed to determine whether once-daily valacyclovir could reduce the risk of sexual transmission of genital herpes.
Methods
Study Population
We enrolled heterosexual couples who were serologically discordant for HSV-2 infection from 96 study sites. The inclusion criteria for the HSV-2–seropositive source partner were an age of 18 years or older, presence of recurrent genital herpes with fewer than 10 episodes per year, and nonuse of any daily antiviral therapy. The inclusion criteria for the susceptible partner were an age of 18 years or older and HSV-2 seronegativity on Western blot analysis. The relationship between the source partner and the susceptible partner was required to be monogamous. Both partners were required to be immunocompetent and in good health and the couple to be using effective contraception.
Study Design
The partners signed separate informed-consent forms that had been approved by local institutional review boards. The partners were seen together at the screening visit, separately at randomization, and at monthly intervals during the eight-month study period. The HSV-2–seropositive partners were randomly assigned, in a 1:1 ratio, to 500 mg of valacyclovir once daily or to matching placebo.23 At each visit, safer sex practices, including the use of condoms during sexual intercourse, were discussed with each partner, and standardized counseling was provided when signs and symptoms of genital herpes were recognized.24 Condoms were provided free of charge to all participants in the trial throughout the study period. For the source partner, adverse experiences and recurrences of genital herpes were recorded on diary cards and reviewed at each clinic visit. The source partners were asked to come to the clinic during recurrences for which episodic therapy with valacyclovir (500 mg twice a day) for five days was offered.25 After the five-day course of valacyclovir had been completed, the source partner resumed taking the randomly assigned medication.
Source partners at four centers were invited to participate in a substudy to define the frequency of reactivation of HSV-2 infection in the genital region. Participants in this substudy were instructed on how to swab the genital secretions every day for two months. Women swabbed the cervicovaginal, vulvar, and perianal regions, and men swabbed the penile skin and perianal area.4,20-22,26 The participants placed the swabs in polymerase-chain-reaction (PCR) buffer and delivered them to the clinic at the next scheduled visit.
During monthly visits by the susceptible partner, serum samples were collected for HSV analysis, and diaries were reviewed for notes concerning sexual activity, condom use, and symptoms suggestive of incident genital herpes during the preceding month.5 The susceptible partners were instructed to visit the clinic if they observed symptoms or lesions compatible with genital herpes. Separate swabs of genital secretions were obtained for HSV culture and HSV DNA detection by PCR and were shipped to the central laboratory at the University of Washington.27,28 If new genital herpes was clinically diagnosed, patients were offered treatment with a licensed dose of valacyclovir.29
Study End Points
Acquisition of HSV-2 infection was defined as the isolation of HSV-2 in culture, the detection of HSV-2 DNA, or HSV-2 seroconversion in the susceptible partner during the course of the trial.2,5,8,15,16 Clinically symptomatic genital herpes was defined according to the presence of clinical signs and symptoms and was confirmed by isolation of HSV-2 in culture, detection of HSV-2 DNA by PCR, or HSV-2 seroconversion. An end-points committee, whose members were blinded to the treatment assignment, reviewed all cases of genital herpes clinically diagnosed during the study. This committee also reviewed all cases in which the susceptible partner had an abnormal genital symptom or sign during the study, as well as all cases of genital herpes confirmed by laboratory analysis.
Laboratory Analyses
All serum was sent to the central laboratory. Serum samples obtained at the time of screening, at the time of randomization, and at one month and eight months were run in parallel on Western blots. Seroconversion was defined according to previously published criteria — namely, the development of one to four new bands, including bands corresponding to HSV-2 glycoprotein G type 2 (gG2) or to HSV type 1 (HSV-1) glycoproteins, such as glycoprotein G type 1 (gG1).5,8,15 Cultures and PCR analyses for HSV were performed as previously described.4,26-28 All isolates from susceptible partners who acquired HSV-2 were tested for their susceptibility to acyclovir by the plaque-reduction assay.30
Statistical Analysis
The predefined primary end point was a laboratory-confirmed, clinically symptomatic first episode of genital HSV-2 infection in the susceptible partner. Secondary end points included the time to overall HSV-2 acquisition (i.e., the occurrence of the primary end point, HSV-2 seroconversion in the susceptible partner, or both) and the time to a first recurrence of genital HSV-2 in the source partner. A 3 percent rate of clinically symptomatic genital herpes (annualized rate, 5 percent) was assumed for placebo.15 Because this study was designed to detect a 75 percent difference between valacyclovir and placebo in the rates of clinically symptomatic disease, we estimated that 28 confirmed cases of genital HSV-2 infection were required for 90 percent power with a two-tailed test of proportions at the 5 percent significance level.31 It was estimated that random assignment of 750 couples to each treatment group would achieve these assumptions. Randomization was performed at a central site in blocks of 10 to ensure balance between the groups. Randomization was stratified according to the sex and HSV-1 status of the susceptible partners.
The two study groups were compared with respect to the primary end point with use of the stratified version of Fisher's exact test.32 Analyses included data from all the subjects who had been randomly assigned to a study group and who took at least one dose of medication. No interim analyses were planned or conducted. The study groups were compared with respect to time-to-event end points with use of the log-rank test, with stratification according to the susceptible partner's sex and HSV-1 status on screening. Hazard ratios were calculated by means of the Cox proportional-hazards model, with covariates defined according to stratum and treatment. Data for subjects who did not reach an end point were censored as event-free periods ending on the last day that the absence of the end point was confirmed. Interaction tests were used to determine whether there was evidence of a differential effect of valacyclovir treatment across subgroups.33 All reported P values are two-sided. Analysis of the data was performed at GlaxoSmithKline, the sponsor of the study. The authors had access to the primary data, directed the analyses, and made all decisions pertaining to the manuscript and its submission for publication.
Results
Demographics
The trial was initiated in February 1998, and the last couple was enrolled in July 2001. Of the 4034 screened couples, 1385 of the susceptible partners (34.3 percent) were HSV-2–positive at the time of screening and hence were ineligible, 799 of the source partners (19.8 percent) were not HSV-2–positive and hence were ineligible, and 352 couples (8.7 percent) declined to take part; hence, 1498 couples (37.1 percent), from 96 sites, proceeded to randomization. Fourteen persons (7 assigned to the valacyclovir group and 7 to the placebo group) elected not to take the study medication, leaving 1484 participating couples. Our analyses were based on data from the 1484 source partners (743 in the valacyclovir group and 741 in the placebo group) who took their assigned study medication. The number of couples at each study center varied from 1 to 141 (median, 8). Of the 1484 participating couples, 803 were in the United States, 118 in Canada, 462 in Europe, 43 in Latin America, and 58 in Australia.
Of the 1484 participating couples, 1159 (78.1 percent) completed the study. Reasons for withdrawal among the remaining 325 couples were based on the source partner's reason and included 82 who withdrew voluntarily (28 assigned to valacyclovir and 54 to placebo), 99 who were lost to follow-up (53 and 46, respectively), 66 whose relationship was dissolved (33 and 33, respectively), 16 who had an adverse event (11 and 5, respectively), 16 for whom there were protocol violations (8 and 8, respectively), 13 who decided to attempt pregnancy (6 and 7, respectively), 9 who reported frequent recurrences while taking the study medication (1 and 8, respectively), and 24 who withdrew for other reasons (18 and 6, respectively). The total number of withdrawals and the reasons for withdrawal were similar for the couples whose source partner was assigned to take valacyclovir (21 percent) and those whose source partner was assigned to take placebo (23 percent). However, voluntary withdrawal was more frequent among source partners who were randomly assigned to placebo than among those who were randomly assigned to valacyclovir (54 vs. 28, P=0.003), probably because of the frequent recurrences among the placebo-treated source partners.
Among the 1484 HSV-2–susceptible subjects, 488 (32.9 percent) were the female partners of men with HSV-2 infection (Table 1Table 1
Demographic and Clinical Characteristics of the HSV-2–Infected (Source) Partners and the HSV-2–Seronegative Susceptible Partners, According to the Source Partner's Treatment Assignment.). Of these women, 383 were seropositive for HSV-1 (78.5 percent). Of the 996 susceptible partners who were men, 641 were HSV-1–seropositive (64.4 percent).Compliance with the medication regimen was high. Overall, 1042 of the 1484 source partners (70.2 percent) reported taking at least 95 percent of the prescribed doses.
Acquisition of HSV Infection and Disease
The end-points committee reviewed data from 71 susceptible partners in whom genitourinary signs and symptoms compatible with new genital herpes developed during the course of the study. Twenty had clinical and laboratory evidence of genital HSV-2 infection associated with these symptoms: in 15 (2 taking valacyclovir and 13 taking placebo) HSV-2 seroconversion (with or without detection of virus) confirmed the diagnosis, and in 5 (2 valacyclovir and 3 placebo) the diagnosis was confirmed by viral culture or HSV PCR only. Of the remaining 51 susceptible partners with genitourinary symptoms, 3 (2 valacyclovir and 1 placebo) had seroconversion to HSV-2 positivity during the study; however, the seroconversion predated the reported symptoms, and hence the new infection was believed to be asymptomatic. In the remaining 48 susceptible partners with genitourinary symptoms, the symptoms were rejected as end points because none of the susceptible partners had laboratory evidence of genital herpes. The source partners of these 48 subjects were almost equally divided between the placebo group (with 25) and the valacyclovir group (with 23). Of the 1413 susceptible partners who did not have symptoms, 18 had seroconversion to HSV-2 and 4 had seroconversion to HSV-1. Thus, a total of 41 HSV-2 infections and 4 HSV-1 infections were detected during the study period. Of these 45 documented infections, 14 were acquired by the sexual partners of subjects who were taking valacyclovir, as compared with 31 partners of subjects who were taking placebo (Table 2Table 2
Acquisition of HSV Infection among the Susceptible Partners, According to the Source Partner's Treatment Assignment. and Figure 1AFigure 1Kaplan–Meier Plots of Time to Acquisition of HSV Infection among Susceptible Sexual Partners of Persons with Genital HSV-2 Infection, According to the Source Partner's Treatment Group.).Of the 41 HSV-2 infections, 20 were associated with symptomatic new genital herpes (the primary end point of the study) and 21 with seroconversion only (Table 2). Of the 20 symptomatic acquisitions of HSV-2, 16 occurred among the 741 partners of placebo recipients (2.2 percent), as compared with 4 among the 743 partners of valacyclovir recipients (0.5 percent) (relative risk, 0.25; 95 percent confidence interval, 0.08 to 0.74; P=0.01). The time to development of a symptomatic first episode of genital herpes was significantly longer among the partners of valacyclovir recipients than among the partners of placebo recipients (Figure 1B). When we evaluated all 41 cases of HSV-2 acquisition, we found that HSV-2 had been acquired by 27 of the susceptible partners of placebo recipients (3.6 percent) as compared with 14 of the susceptible partners of valacyclovir recipients (1.9 percent) (hazard ratio, 0.52; 95 percent confidence interval, 0.27 to 0.99; P=0.04) (Table 2 and Figure 1C). More female partners than male partners of placebo-treated subjects acquired HSV-2 infection (7.4 percent vs. 1.8 percent) (Table 3Table 3
Rates of Transmission of HSV-2 Infection to Susceptible Partners, According to Risk Stratum. and Figure 1D). Time-to-event analysis revealed no evidence of a significant difference in treatment effect between susceptible female and male partners (P=0.73 by the interaction test) (Figure 1D).HSV Reactivation and Shedding among Source Partners
Among the 741 source partners assigned to take placebo, 573 reported a genital recurrence during the study (77.3 percent), as compared with 288 of the 743 assigned to take valacyclovir (38.8 percent) (P<0.001). Valacyclovir significantly prolonged the time to a first recurrence (hazard ratio, 0.30; 95 percent confidence interval, 0.26 to 0.35; P<0.001). The mean rate of recurrence was 0.40 per month among the source partners taking placebo as compared with 0.11 per month among those taking valacyclovir (P<0.001).
The 89 source partners participating in the shedding substudy (68 women and 21 men) collected daily samples of genital secretions for a median of 58 days. Overall, HSV was detected by PCR on 2.9 percent of the days among the 39 source partners taking valacyclovir as compared with 10.8 percent of the days among the 50 source partners taking placebo (P<0.001). Shedding was detected in 19 of 39 valacyclovir-treated partners (48.7 percent), as compared with 41 of 50 placebo-treated partners (82.0 percent) (relative risk, 0.60; 95 percent confidence interval, 0.43 to 0.83; P=0.002). The difference in shedding was seen in both men and women. In only 3 of 39 valacyclovir-treated source partners (7.7 percent) was HSV DNA detected on at least 10 percent of the days, as compared with 25 of 50 placebo-treated source partners (50.0 percent, P<0.001) (Figure 2AFigure 2
Frequency and Titer of HSV-2 Shedding among Valacyclovir-Treated as Compared with Placebo-Treated Source Partners.). Shedding occurred on 3.3 percent and 0.9 percent of the days among the valacyclovir-treated women and men, respectively, as compared with 11.4 percent and 9.2 percent of the days among placebo-treated women and men. The median number of genome copies of HSV DNA from positive mucosal-swab specimens was 1×103.1 in the valacyclovir group and 1×105.4 in the placebo group (P<0.001) (Figure 2B).Sexual Activity, Condom Use, and Covariates of Transmission
The median number of sexual contacts per couple during the study was 49 in the valacyclovir group and 46 in the placebo group (range, 0 to 482). The frequency of genital HSV-2 acquisition increased with the reported frequency of sexual activity and was 0.35 per 1000 sexual contacts among the susceptible partners of valacyclovir recipients, as compared with 0.68 per 1000 sexual contacts among the susceptible partners of placebo recipients. The respective rates of acquisition among susceptible women were 0.60 and 1.27 per 1000 sexual contacts and, among susceptible men, 0.23 and 0.35 per 1000 sexual contacts.
Despite counseling, 37 percent of the couples reported at each monthly visit that they never used condoms for vaginal or anal intercourse at all during the study, 20 percent reported that they used condoms more than 90 percent of the time, and 43 percent reported that they used them between 1 and 90 percent of the time. Although rates of transmission of HSV-2 were lower in the valacyclovir group than in the placebo group for all levels of condom use (Table 3), there was considerable overlap between the groups in the rates of acquisition (see Supplementary Appendix 1, available with the full text of this article at www.nejm.org).
Exploratory covariate analyses were performed for both clinical and overall HSV-2 acquisition. Condom use was defined as a time-dependent covariate. In these multivariate analyses, factors found to influence the risk of HSV-2 transmission significantly were female sex of the susceptible partner, greater number of sexual contacts, and shorter duration of genital herpes in the source partner (Table 3 and Table 4Table 4
Covariate Analyses of Factors Influencing the Transmission of Genital Herpes.). There was no evidence that valacyclovir had a reduced therapeutic effect when efficacy was examined among subgroups defined by these covariates.Adverse Effects and Susceptibility of Isolates from Cases of Acquisition
The frequency of adverse effects was similar in the placebo and valacyclovir groups and was similar to those reported in studies of valacyclovir in immunocompetent persons with genital herpes.23,25,29 No serious adverse events were considered by the investigators to be related to use of the study medication. HSV-2 isolates were available for sensitivity testing from 11 of the 20 cases of symptomatic new infection. All 11 isolates were sensitive to acyclovir, with plaque-neutralization titers of less than 0.2 μg per milliliter.30
Discussion
Our study demonstrates that oral valacyclovir taken by immunocompetent persons with recurrent genital HSV-2 infection significantly reduces the rates of HSV reactivation, subclinical shedding, and transmission of genital herpes to a susceptible partner. A 500-mg dose of valacyclovir taken once daily reduced the risks of acquisition of symptomatic genital herpes and acquisition of HSV-2 infection overall by susceptible, HSV-2–seronegative heterosexual partners. The results of the trial demonstrate the effectiveness of treating the source partner with an antiviral agent to reduce the risk of transmission of a sexually transmitted viral disease. The results were in addition to any effects that may have been attributable to counseling or safer-sex practices used by the study population.
People with genital herpes and their sexual partners consider the transmission of this infection their chief concern.17 Adding to this concern are data showing that HSV-2–seropositive persons have an increased risk of infection with the human immunodeficiency virus11-14,34 and that new HSV-2 infection during late pregnancy poses a high risk of transmission of HSV-2 to the neonate.35 Condoms are partially effective in reducing HSV-2 transmission and, along with abstinence during outbreaks, should continue to be recommended.36 Our trial was conducted among couples who received monthly counseling about the use of condoms for reducing the risk of transmission of HSV-2 infection and other sexually transmitted infections and who were offered free condoms. Yet, 37 percent of the couples reported no condom use during the trial. Covariate analyses accounting for reported condom use indicated that valacyclovir use continued to be associated with reduced rates of transmission. The lowest observed rates of transmission were among couples who reported that they almost always used condoms and in whom the source partner was taking valacyclovir. However, our study does not allow us to define what levels of condom use in combination with valacyclovir therapy provide optimal or suboptimal protection.
We studied persons with recurrent genital herpes who were already candidates for antiviral suppression. Prevention of transmission of HSV infection is an added benefit to the relief of clinically symptomatic disease in such persons. According to the overall rate of HSV-2 acquisition that we observed and the 48 percent reduction in risk with valacyclovir, one would expect to treat 38 persons with recurrent genital herpes for a year to prevent one case of HSV-2 infection in a susceptible partner. However, this number varies according to the sex of the susceptible partner, frequency of condom use, duration of the relationship, and other variables that influence the likelihood of transmission. Thus, in our study, the annualized number needed to treat is 11 for couples in which the susceptible woman's partner will not use condoms and 24 for couples with the highest level of sexual activity.
The frequency of acquisition of HSV-2 infection in our trial was lower than in trials of HSV-2 acquisition conducted in observational cohorts and other discordant partnerships, probably because of the low biologic risk of infection among long-standing couples, the high proportion of susceptible male participants, and the extensive counseling we performed.7,15,16,37,38 If one used the annualized incidence of 11.4 percent, derived from a recent trial of vaccination to prevent HSV infection in seronegative subjects,16 the overall number of persons needed to treat would be 18 to prevent one transmission. If one used data from an observational cohort study of susceptible pregnant women with HSV-2–seropositive partners, the number needed to treat would be 11.37 The lower rate of transmission from HSV-2–infected women to men makes this figure two to three times higher in discordant couples in which the susceptible partner is female.
To what extent can we extrapolate both the biologic and cost-effectiveness aspects of the data in this study to other settings? It is likely that the transmission effects we found are applicable to nonmonogamous heterosexual couples. Valacyclovir is effective in suppressing genital herpes in men who have sex with men.39 However, as shown in the trial, sexual transmission is influenced by sexual behavior and biologic factors. Most instances of HSV-2 transmission occur with source partners who do not have a history of genital herpes,5,15,38 and few studies describing daily antiviral medication in such persons are available. Additional studies to evaluate whether suppressive therapy will prevent transmission among couples with a source partner with subclinical HSV-2 infection, couples in whom the susceptible partner is immunocompromised, and homosexual couples should be undertaken. Studies in which the susceptible partner is pregnant are of special importance because of the high risk of acquisition of HSV-1 or HSV-2 infection in this setting. The few cases of asymptomatic HSV-1 acquisition in this study were not sufficient to allow us to determine whether valacyclovir would reduce the risk of HSV-1 transmission.
Because the observed reduction in the rate of transmission of genital herpes with valacyclovir is clinically relevant but not complete, it is important that disclosure of genital herpes to the susceptible partner and the practice of safer sex continue, since both may reduce the risk of transmission of genital herpes.
Supported by GlaxoSmithKline Research and Development and a grant (AI-30731) from the National Institutes of Health.
Dr. Corey reports supervision of laboratories that perform work on a contract basis for GlaxoSmithKline, Novartis, and 3M. Dr. Wald reports having received consultation fees from Biovail, Eli Lilly, and Novartis and lecture fees from GlaxoSmithKline. Dr. Patel reports having received consultation and lecture fees from GlaxoSmithKline and Novartis, consultation fees from Eli Lilly and 3M, and grant support from GlaxoSmithKline and reports holding equity in GlaxoSmithKline. Dr. Sacks reports having received consultation and lecture fees from GlaxoSmithKline and Novartis and holding equity in Viridae Clinical Sciences. Dr. Tyring reports having received consultation and lecture fees and grant support from GlaxoSmithKline. Dr. Warren reports having received consultation and lecture fees from GlaxoSmithKline. Dr. Douglas reports having received lecture fees from GlaxoSmithKline. Dr. Paavonen reports having received speakers' honorariums from GlaxoSmithKline. Dr. Morrow reports having received consultation fees from Bio-Rad, Focus, GlaxoSmithKline, and Novartis; lecture fees from Quest Diagnostics and Quadrant Health; and grant support from Trinity Bio-Tech. Dr. Beutner reports having received consultation and lecture fees from GlaxoSmithKline, Eli Lilly, and 3M. Dr. Mertz reports having received consultation fees from GlaxoSmithKline and Eli Lilly, lecture fees from GlaxoSmithKline, and grant support from 3M.
This article is dedicated to the memory of Stephen L. Sacks, M.D., whose research on genital herpes contributed substantially to our findings.
We are indebted to the 1498 couples, the investigators, and the study staff for their tremendous contribution to this demanding trial; to Julia Harris and Judith Zeh, statisticians, for their contributions to the analyses and study design, respectively; to Stacy Selke for her role in management of the data; to Zane Brown and Dorothea Griffiths for their work on the End-Points Committee; and to Alison Webster, Robert Deeter, and Karen Coates, all of GlaxoSmithKline, for their assistance.
Source Information
From the Departments of Medicine (L.C., A.W.), Laboratory Medicine (L.C., R.A.M.), and Epidemiology (A.W.), University of Washington, Seattle; the Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle (L.C.); the Department of Genitourinary Medicine, Royal South Hants Hospital, Southampton, United Kingdom (R.P.); Viridae Clinical Sciences and University of British Columbia, Vancouver, Canada (S.L.S.); the University of Texas Medical Branch, Galveston (S.K.T.); Westover Heights Clinic, Portland, Oreg. (T.W.); the Disease Control Service, Denver Department of Public Health, Denver (J.M.D.); the Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland (J.P.); Dow Pharmaceutical Sciences and Department of Dermatology, University of California, San Francisco (K.R.B.); the Department of Clinical Pharmacology, Smolensk State Medical Academy, Smolensk, Russia (L.S.S.); the Department of Medicine, University of New Mexico, Albuquerque (G.M.); and the Departments of Biomedical Data Sciences (O.N.K.) and Antiviral Clinical Research (H.A.W., D.T., M.V.-C.), GlaxoSmithKline Research and Development, Greenford, United Kingdom.
Address reprint requests to Dr. Corey at the Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Rm. D3-100, P.O. Box 19024, Seattle, WA 98109, or at lcorey@u.washington.edu.
Members of the Valacyclovir Herpes Simplex Virus (HSV) Transmission Study Group are listed in the Appendix.
Appendix
The members of the Valacyclovir HSV Transmission Study Group are as follows: J. McCloskey, I. Denham, J. Patten, C. Pell, and R. Waddell (Australia); C.T. Sodre (Brazil); C. Bouchard, F.J. Diaz-Mitoma, M.G. Lassonde, B. Romanowski, S.L. Sacks, and S. Trottier (Canada); W. Gubelin and A. Guglielmetti (Chile); J. Diaz and N. Rubiano (Colombia); J. Roed-Petersen, K. Thestrup-Pedersen, and H.C. Wulff (Denmark); K. Kivimagi and A. Poder (Estonia); J. Paavonen, S. Saari, and A.-L. Simpanen (Finland); P. Morel and J.P. Ortonne (France); E. Cardamakis and O. Mourelou (Greece); J. Bornstein and M. Dolitzky (Israel); B. Dainys and A. Laiskonis (Lithuania); R.G. Soto and V.H. Pulido Olivares (Mexico); I. Cairo (the Netherlands); V. Arama, V. Balasoiu, M. Capalna, C. Giurcaneanu, S. Popescu, and V. Tarlea (Romania); A. Koubanova, L. Martchenko, T. Semenova, and L. Stratchounsky (Russia); J. Ballesteros and J.A. Varela (Spain); A. Strand (Sweden); N. Atakan and G. Ozarmagan (Turkey); C. Bowman and R. Patel (United Kingdom); and G.M. Adkins, D.A. Baker, K.R. Beutner, R.A. Beyerlein, R. Brady, M. Cabezas-Mijuste, S. Clark, M. Conant, L. Corey, M.A. Drehobl, J. Douglas, S. Faro, K.H. Fife, S. Funk, D. Gartman, G. Garza, D.C. Hart, J.A. Holmes, W.D. Koltun, S.J. Kraus, T. Kurtz, M.A. Landwermeyer, P.A. Leone, M.J. Levin, T.C. Marbury, S.I. Marlowe, A. Marques, G. Mertz, R. Nett, B. Pogue, D.M. Portez, J. Rosen, D.H. Rowe, G. Salazar, T.W. Schacker, M. Seraly, R.P. Spencer, J. Stern, S. Stone, E. Thomas, S.K. Tyring, A. Wald, T. Warren, D.A. Whiting, M.L. Wiener, and H. Wiesenfeld (United States).
- References
References
1
Corey L, Wald A. Genital herpes. In: Holmes KK, Mårdh P-A, Sparling PF, et al., ed. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999:285-312.
2
Ashley R ,Wald A . Genital herpes: review of the epidemic and potential uses of type-specific serology. Clin Microbiol Rev 1999;12:1-8
Web of Science | Medline3
Benedetti J ,Corey L ,Ashley R . Recurrence rates of genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847-854
Web of Science | Medline4
Wald A ,Zeh J ,Selke S ,Ashley RL ,Corey L . Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995;333:770-775
Full Text | Web of Science | Medline5
Langenberg AGM ,Corey L ,Ashley RL ,Leong WP ,Straus SE . A prospective study of new infections with herpes simplex virus type 1 and type 2. N Engl J Med 1999;341:1432-1438
Full Text | Web of Science | Medline6
Rooney JF ,Felser JM ,Ostrove JM ,Straus SE . Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med 1986;314:1561-1564
Full Text | Web of Science | Medline7
Mertz GJ ,Coombs RW ,Ashley RL , et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis 1988;157:1169-1177
CrossRef | Web of Science | Medline8
Mertz GJ ,Schmidt O ,Jourden JL , et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-39
CrossRef | Web of Science | Medline9
Fleming DT ,McQuillan GM ,Johnson RE , et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-1111
Full Text | Web of Science | Medline10
Armstrong G ,Schillinger J ,Markowitz L , et al. Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001;153:912-920
CrossRef | Web of Science | Medline11
Beyrer C ,Jitwatcharanan K ,Natpratan C , et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998;178:243-246
CrossRef | Web of Science | Medline12
Chen CY ,Ballard RC ,Beck-Sague CM , et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000;27:21-29
CrossRef | Web of Science | Medline13
Mwansasu A ,Mwakagile D ,Haarr L ,Langeland N . Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. J Clin Virol 2002;24:183-192
CrossRef | Web of Science | Medline14
Wald A ,Link K . Risk of human immunodeficiency virus infection in herpes simplex virus type-2 seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52
CrossRef | Web of Science | Medline15
Corey L ,Langenberg AGM ,Ashley R , et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized, controlled trials. JAMA 1999;282:331-340
CrossRef | Web of Science | Medline16
Stanberry LR ,Spruance SL ,Cunningham AL , et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-1661
Full Text | Web of Science | Medline17
Carney O ,Ross E ,Bunker C ,Ikkos G ,Mindel A . A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994;70:40-45
Medline18
Douglas JM ,Critchlow C ,Benedetti J , et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310:1551-1556
Full Text | Web of Science | Medline19
Goldberg LH ,Kaufman R ,Kurtz TO , et al. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch Dermatol 1993;129:582-587
CrossRef | Web of Science | Medline20
Wald A ,Corey L ,Cone R ,Hobson A ,Davis G ,Zeh J . Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997;99:1092-1097
CrossRef | Web of Science | Medline21
Wald A, Warrant T, Hu H, et al. Suppression of subclinical shedding of herpes simplex virus type 2 in the genital tract with valaciclovir. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 24–27, 1998. Washington, D.C.: American Society for Microbiology, 1998:338. abstract.
22
Sacks SL, Hughes A, Rennie B, Boon R. Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: a randomized double-blind, double-dummy, parallel-group, placebo-controlled trial. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997:227. abstract.
23
Patel R ,Bodsworth NJ ,Woolley P , et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997;73:105-109
Medline24
Genital herpes: a patient guide to treatment. Chicago: American Medical Association, 1997.
25
Spruance SL ,Tyring SK ,DeGregorio B ,Miller C ,Beutner K . A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996;156:1729-1735
CrossRef | Web of Science | Medline26
Wald A ,Zeh J ,Selke S , et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342:844-850
Full Text | Web of Science | Medline27
Ryncarz AJ ,Goddard J ,Wald A ,Huang ML ,Roizman B ,Corey L . Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 1999;37:1941-1947
Web of Science | Medline28
Jerome KR ,Huang ML ,Wald A ,Selke S ,Corey L . Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002;40:2609-2611
CrossRef | Web of Science | Medline29
Fife KH ,Barbarash RA ,Rudolph T ,Degregorio B ,Roth R . Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481-486
CrossRef | Web of Science | Medline30
Bacon TH ,Levin JM ,Leary J ,Sarisky RT ,Sutton D . Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16:114-128
CrossRef | Web of Science | Medline31
Gart JJ . Point and interval estimation of the common odds ratio in the combination of 2×2 tables with fixed marginals. Biometrika 1970;57:471-475
Web of Science32
Shuster JJ . Fixing the number of events in large comparative trials with low event rates: a binomial approach. Control Clin Trials 1993;14:198-208
CrossRef | Medline33
Zelen M . The analysis of several 2×2 contingency tables. Biometrika 1971;58:129-137
Web of Science34
Stamm W ,Handsfield HH ,Rompalo AM ,Ashley RL ,Roberts PL ,Corey L . The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988;260:1429-1433
CrossRef | Web of Science | Medline35
Brown ZA ,Wald A ,Morrow RA ,Selke S ,Zeh J ,Corey L . Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-209
CrossRef | Web of Science | Medline36
Wald A ,Langenberg AGM ,Link K , et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-3106
CrossRef | Web of Science | Medline37
Gardella C, Ashley R, Berry S, et al. The risk of acquisition of herpes simplex virus during pregnancy: a prospective couples study. Presented at the Annual Research Meeting of the Infectious Diseases Society for Obstetrics and Gynecology, Quebec City, Canada, August 9–11, 2001. abstract.
38
Wald A, Selke S, Lowens S, et al. Sexual transmission of genital HSV: risk factors in a time-to-event analysis. In: Program and abstracts of STIs at the Millennium: Joint Meeting of the American Sexually Transmitted Diseases Association/Medical Society for the Study of Venereal Diseases, Baltimore, May 3–7, 2000. abstract.
39
Conant MA ,Schacker TW ,Murphy RL ,Gold J ,Crutchfield LT ,Crooks RJ . Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002;13:12-21
CrossRef | Web of Science | Medline
- Citing Articles (165)
Citing Articles
1
Philippe Van de Perre, Nicolas Nagot. (2012) Herpes simplex virus: a new era?. The Lancet
CrossRef2
Christine Johnston, Misty Saracino, Steve Kuntz, Amalia Magaret, Stacy Selke, Meei-li Huang, Joshua T Schiffer, David M Koelle, Lawrence Corey, Anna Wald. (2012) Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. The Lancet
CrossRef3
Anita Arora, Natalia Mendoza, Stephen K. Tyring. 2011. Antiviral Market Overview. .
CrossRef4
Carolyn Gardella. (2011) Herpes Simplex Virus Genital Infections: Current Concepts. Current Infectious Disease Reports 13:6, 588-594
CrossRef5
Christine Johnston, David M. Koelle, Anna Wald. (2011) HSV-2: in pursuit of a vaccine. Journal of Clinical Investigation 121:12, 4600-4609
CrossRef6
Arlene C. Sena, Peter Leone. (2011) Utility of Episodic Acyclovir Therapy for HSV-2 in Africa. Sexually Transmitted Diseases1
CrossRef7
Ádám Galamb, Zoltán Langmár. (2011) Connatalis fertőzések gyakorlati vonatkozásai – megelőzés, diagnosztika és kezelés. Orvosi Hetilap 152:46, 1849-1854
CrossRef8
J. T. Schiffer, A. Magaret, S. Selke, L. Corey, A. Wald. (2011) Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. Journal of Antimicrobial Chemotherapy 66:11, 2593-2600
CrossRef9
Eric Strachan, Misty Saracino, Stacy Selke, Amalia Magaret, Dedra Buchwald, Anna Wald. (2011) The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women. Brain, Behavior, and Immunity 25:7, 1475-1481
CrossRef10
Alexander Birkmann, Guy Hewlett, Helga Rübsamen-Schaeff, Holger Zimmermann. (2011) Helicase–primase inhibitors as the potential next generation of highly active drugs against herpes simplex viruses. Future Virology 6:10, 1199-1209
CrossRef11
Kerry J. Laing, Lichun Dong, John Sidney, Alessandro Sette, David M. Koelle. (2011) T-cell responses to herpes simplex viruses. Clinical & Experimental Immunologyno-no
CrossRef12
Luciana Scalone, Verity Watson, Mandy Ryan, Nikolaos Kotsopoulos, Rajul Patel. (2011) Evaluation of Patientsʼ Preferences for Genital Herpes Treatment. Sexually Transmitted Diseases 38:9, 802-807
CrossRef13
Graciela Andrei, Robert Snoeck. (2011) Emerging drugs for varicella-zoster virus infections. Expert Opinion on Emerging Drugs 16:3, 507-535
CrossRef14
Michael Isiah Sandlin, Christine Johnston, David Bowe, Misty Saracino, Timothy Schacker, Mary Shaughnessy, Lawrence Corey, Anna Wald. (2011) Clinician and Patient Recognition of Anogenital Herpes Disease in HIV Positive Men Who Have Sex With Men. Sexually Transmitted Diseases 38:9, 833-836
CrossRef15
Daniel Suissa, Paul Brassard, Brielan Smiechowski, Samy Suissa. (2011) Number needed to treat is incorrect without proper time-related considerations. Journal of Clinical Epidemiology
CrossRef16
Myron S. Cohen, Joseph J. Eron. (2011) Aciclovir Treatment for Human Immunodeficiency Virus-1: Is the “Juice Worth the Squeeze?”. Sexually Transmitted Diseases 38:5, 410-412
CrossRef17
Laurence Le Cleach, Ludovic Trinquart, Benedicte Lebrun-Vignes, Bruno Giraudeau, Olivier Chosidow, Laurence Le Cleach. 2011. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. .
CrossRef18
Catriona Ooi, Vijay Zawar. (2011) Hyperaesthesia Following Genital Herpes: A Case Report. Dermatology Research and Practice 2011, 1-3
CrossRef19
Ashleigh R. Tuite, David N. Fisman. (2011) Spectrum Bias and Loss of Statistical Power in Discordant Couple Studies of Sexually Transmitted Infections. Sexually Transmitted Diseases 38:1, 50-56
CrossRef20
C Gardella, Z Brown. (2011) Prevention of neonatal herpes. BJOG: An International Journal of Obstetrics & Gynaecology 118:2, 187-192
CrossRef21
Abhinav Grover, Vibhuti Agrawal, Ashutosh Shandilya, Virendra S Bisaria, Durai Sundar. (2011) Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A. BMC Bioinformatics 12:Suppl 13, S22
CrossRef22
Angela Shaulov Kask, Xianfeng Chen, Joshua O. Marshak, Lichun Dong, Misty Saracino, Dexiang Chen, Courtney Jarrahian, Mark A. Kendall, David M. Koelle. (2010) DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 28:47, 7483-7491
CrossRef23
Nicholas Nguyen, Craig N. Burkhart, Craig G. Burkhart. (2010) Review: Identifying potential pitfalls in conventional herpes simplex virus management. International Journal of Dermatology 49:9, 987-993
CrossRef24
Enrique R. Pouget, Trace S. Kershaw, Kim M. Blankenship, Jeannette R. Ickovics, Linda M. Niccolai. (2010) Racial/Ethnic Disparities in Undiagnosed Infection With Herpes Simplex Virus Type 2. Sexually Transmitted Diseases 37:9, 538-543
CrossRef25
S. Guy Mahiane, Eugène-P. Ndong Nguéma, Carel Pretorius, Bertran Auvert. (2010) Mathematical models for coinfection by two sexually transmitted agents: the human immunodeficiency virus and herpes simplex virus type 2 case. Journal of the Royal Statistical Society: Series C (Applied Statistics)no-no
CrossRef26
C. M. Wetmore, L. E. Manhart, J. N. Wasserheit. (2010) Randomized Controlled Trials of Interventions to Prevent Sexually Transmitted Infections: Learning From the Past to Plan for the Future. Epidemiologic Reviews 32:1, 121-136
CrossRef27
Natalia J. Reszka, Timothy Dudek, David M. Knipe. (2010) Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 28:15, 2754-2762
CrossRef28
Anna Wald, Patti E Gravitt, Rhoda A Morrow. 2010. Sexually Transmitted Infections. , 370-382.
CrossRef29
Damjan S Nikolic, Vincent Piguet. (2010) Vaccines and Microbicides Preventing HIV-1, HSV-2, and HPV Mucosal Transmission. Journal of Investigative Dermatology 130:2, 352-361
CrossRef30
Gail F. Shust, Sylvia Cho, Mimi Kim, Rebecca P. Madan, Esmeralda M. Guzman, Margaret Pollack, Julia Epstein, Hillel W. Cohen, Marla J. Keller, Betsy C. Herold. (2010) ORIGINAL ARTICLE: Female Genital Tract Secretions Inhibit Herpes Simplex Virus Infection: Correlation with Soluble Mucosal Immune Mediators and Impact of Hormonal Contraception. American Journal of Reproductive Immunology 63:2, 110-119
CrossRef31
Chris L McGowin, Richard B Pyles. (2010) Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy. Future Microbiology 5:1, 15-22
CrossRef32
Suk Bong Koh. (2010) Management of skin lesion of female external genitalia. Korean Journal of Obstetrics and Gynecology 53:12, 1047
CrossRef33
Hossein Sadeghi-Nejad, Marlene Wasserman, Wolfgang Weidner, Daniel Richardson, David Goldmeier. (2010) Sexually Transmitted Diseases and Sexual Function. Journal of Sexual Medicine 7:1pt2, 389-413
CrossRef34
J. T. Schiffer, L. Abu-Raddad, K. E. Mark, J. Zhu, S. Selke, A. Magaret, A. Wald, L. Corey. (2009) Frequent Release of Low Amounts of Herpes Simplex Virus from Neurons: Results of a Mathematical Model. Science Translational Medicine 1:7, 7ra16-7ra16
CrossRef35
Joshua T. Schiffer, Lawrence Corey. (2009) New concepts in understanding genital herpes. Current Infectious Disease Reports 11:6, 457-464
CrossRef36
Kenneth H. Fife, Barbara Van Der Pol, Alexis M. Roth, Juanita Brand, Janet N. Arno, Jyl Madlem, Beth E. Juliar, Barry P. Katz, James A. Williams, Gregory D. Zimet, J Dennis Fortenberry. (2009) Implementation of Routine Access to Herpes Simplex Virus Type 2 Antibody Testing in a Public Health Sexually Transmitted Disease Clinic. Sexually Transmitted Diseases 36:11, 724-728
CrossRef37
John M. Douglas, Stuart M. Berman. (2009) Screening for HSV-2 Infection in STD Clinics and Beyond: A Few Answers But More Questions. Sexually Transmitted Diseases 36:11, 729-731
CrossRef38
Matthew Hogben, Gale R Burstein, Matthew R Golden. (2009) Partner notification in the clinicianʼs office: patient health, public health and interventions. Current Opinion in Obstetrics and Gynecology 21:5, 365-370
CrossRef39
Corey, Lawrence, Wald, Anna, . (2009) Maternal and Neonatal Herpes Simplex Virus Infections. New England Journal of Medicine 361:14, 1376-1385
Full Text40
Jia Zhu, Florian Hladik, Amanda Woodward, Alexis Klock, Tao Peng, Christine Johnston, Michael Remington, Amalia Magaret, David M Koelle, Anna Wald, Lawrence Corey. (2009) Persistence of HIV-1 receptor–positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nature Medicine 15:8, 886-892
CrossRef41
Suissa, Samy, . (2009) Calculation of Number Needed to Treat. New England Journal of Medicine 361:4, 424-425
Full Text42
Sarah S Wilson, Esra Fakioglu, Betsy C Herold. (2009) Novel approaches in fighting herpes simplex virus infections. Expert Review of Anti-infective Therapy 7:5, 559-568
CrossRef43
Anna M. Foss, Peter T. Vickerman, Zaid Chalabi, Philippe Mayaud, Michel Alary, Charlotte H. Watts. (2009) Dynamic Modeling of Herpes Simplex Virus Type-2 (HSV-2) Transmission: Issues in Structural Uncertainty. Bulletin of Mathematical Biology 71:3, 720-749
CrossRef44
Carolyn Gardella, Elizabeth Krantz, Constance Daruthayan, Linda Drolette, Lawrence Corey, Anna Wald. (2009) The Acceptance of HSV-Testing Partners of HSV-2 Seronegative Pregnant Women. Sexually Transmitted Diseases 36:4, 211-215
CrossRef45
Barbara Romanowski, Linda N. Myziuk, Sharon L. Walmsley, Sylvie Trottier, Ameeta E. Singh, Stanley Houston, Mark Joffe, Isabelle Chiu. (2009) Seroprevalence and Risk Factors for Herpes Simplex Virus Infection in a Population of HIV-Infected Patients in Canada. Sexually Transmitted Diseases 36:3, 165-169
CrossRef46
Irene E Aga, Lisa M Hollier. (2009) Managing genital herpes infections in pregnancy. Women's Health 5:2, 165-174
CrossRef47
Wendy S. Biggs, Rachel M. Williams. (2009) Common Gynecologic Infections. Primary Care: Clinics in Office Practice 36:1, 33-51
CrossRef48
J.M. Martín, G. Villalón, E. Jordá. (2009) Actualización en el tratamiento del herpes genital. Actas Dermo-Sifiliográficas 100:1, 22-32
CrossRef49
Esther E. Freeman, Richard G. White, Roel Bakker, Kate K. Orroth, Helen A. Weiss, Anne Buvé, Richard J. Hayes, Judith R. Glynn. (2009) Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine 27:6, 940-946
CrossRef50
Séverin-Guy Mahiane, Camille Legeai, Dirk Taljaard, Aurélien Latouche, Adrian Puren, Aurélie Peillon, Jean Bretagnolle, Pascale Lissouba, Eugène-Patrice Ndong Nguéma, Elisabeth Gassiat, Bertran Auvert. (2009) Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. AIDS 23:3, 377-383
CrossRef51
Cheryl A. Jones. (2009) Vertical Transmission of Genital Herpes. Drugs 69:4, 421-434
CrossRef52
Mark G. Martens, Kenneth H. Fife, Peter A. Leone, Lynn P. Dix, Clare A. Brennan. (2009) Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes. Infectious Diseases in Obstetrics & Gynecology 2009, 1-7
CrossRef53
Dean V. Coonrod, Brian W. Jack, Phillip G. Stubblefield, Lisa M. Hollier, Kim A. Boggess, Robert Cefalo, Shanna N. Cox, Anne L. Dunlop, Kam D. Hunter, Mona R. Prasad, Michael C. Lu, Jeanne A. Conry, Ronald S. Gibbs, Vijaya K. Hogan. (2008) The clinical content of preconception care: infectious diseases in preconception care. American Journal of Obstetrics and Gynecology 199:6, S296-S309
CrossRef54
Lisa M. Hollier, Kimberly Workowski. (2008) Treatment of Sexually Transmitted Infections in Women. Infectious Disease Clinics of North America 22:4, 665-691
CrossRef55
Susan S. Philip, Katherine Ahrens, Clara Shayevich, Romeo de la Roca, MaryAnn Williams, Daniel Wilson, Kyle Bernstein, Jeffrey D. Klausner. (2008) Evaluation of a New Point‐of‐Care Serologic Assay for Herpes Simplex Virus Type 2 Infection. Clinical Infectious Diseases 47:10, e79-e82
CrossRef56
(2008) Guidelines for reducing the risk of viral transmission during fertility treatment. Fertility and Sterility 90:5, S156-S162
CrossRef57
Erik De Clercq. (2008) The discovery of antiviral agents: Ten different compounds, ten different stories. Medicinal Research Reviews 28:6, 929-953
CrossRef58
Gregory J. Mertz. (2008) Asymptomatic Shedding of Herpes Simplex Virus 1 and 2: Implications for Prevention of Transmission. The Journal of Infectious Diseases 198:8, 1098-1100
CrossRef59
Karen E. Mark, Anna Wald, Amalia S. Magaret, Stacy Selke, Laura Olin, Meei‐Li Huang, Lawrence Corey. (2008) Rapidly Cleared Episodes of Herpes Simplex Virus Reactivation in Immunocompetent Adults. The Journal of Infectious Diseases 198:8, 1141-1149
CrossRef60
Jennifer S. Read, Michael J. Cannon, Lawrence R. Stanberry, Susan Schuval. (2008) Prevention of Mother-to-Child Transmission of Viral Infections. Current Problems in Pediatric and Adolescent Health Care 38:9, 274-297
CrossRef61
Julia A. Schillinger, Christy M. McKinney, Renu Garg, R Charon Gwynn, Kellee White, Francis Lee, Susan Blank, Lorna Thorpe, Thomas Frieden. (2008) Seroprevalence of Herpes Simplex Virus Type 2 and Characteristics Associated With Undiagnosed Infection: New York City, 2004. Sexually Transmitted Diseases 35:6, 599-606
CrossRef62
Rhoda S. Sperling, Kenneth H. Fife, Terri J. Warren, Lynn P. Dix, Clare A. Brennan. (2008) The Effect of Daily Valacyclovir Suppression on Herpes Simplex Virus Type 2 Viral Shedding in HSV-2 Seropositive Subjects Without a History of Genital Herpes. Sexually Transmitted Diseases 35:3, 286-290
CrossRef63
Richard Rupp, David I Bernstein. (2008) The potential impact of a prophylactic herpes simplex vaccine. Expert Opinion on Emerging Drugs 13:1, 41-52
CrossRef64
David M. Koelle, Lawrence Corey. (2008) Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annual Review of Medicine 59:1, 381-395
CrossRef65
H Nina Kim, Anna Wald, Julia Harris, Jennifer Almekinder, Cathy Heitman, Lawrence Corey. (2008) Does Frequency of Genital Herpes Recurrences Predict Risk of Transmission? Further Analysis of the Valacyclovir Transmission Study. Sexually Transmitted Diseases 35:2, 124-128
CrossRef66
Valérie Martinez, Eric Caumes, Olivier Chosidow. (2008) Treatment to prevent recurrent genital herpes. Current Opinion in Infectious Diseases 21:1, 42-48
CrossRef67
Lisa M Hollier, George D Wendel, Lisa M Hollier. 2008. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. .
CrossRef68
W. Lawrence Drew, Kim S. Erlich. 2008. Management of Herpesvirus Infections (Cytomegalovirus, Herpes Simplex Virus, and Varicella-Zoster Virus). , 437-461.
CrossRef69
Carolyn Gardella, Julia Barnes, Amalia S. Magaret, Julie Richards, Linda Drolette, Anna Wald. (2007) Prenatal Herpes Simplex Virus Serologic Screening Beliefs and Practices Among Obstetricians. Obstetrics & Gynecology 110:6, 1364-1370
CrossRef70
Rachna Gupta, Terri Warren, Anna Wald. (2007) Genital herpes. The Lancet 370:9605, 2127-2137
CrossRef71
Karin Batalden, Corinne Bria, Frank M. Biro. (2007) Genital Herpes and the Teen Female. Journal of Pediatric and Adolescent Gynecology 20:6, 319-321
CrossRef72
Colette Smit, Christiaan Pfrommer, Adrian Mindel, Janette Taylor, Joke Spaargaren, Ben Berkhout, Roel Coutinho, Nicole H. T. M. Dukers. (2007) Rise in seroprevalence of herpes simplex virus type 1 among highly sexual active homosexual men and an increasing association between herpes simplex virus type 2 and HIV over time (1984–2003). European Journal of Epidemiology 22:12, 937-944
CrossRef73
Brian Conway. (2007) Genital herpes: the undiscovered pandemic. Future Virology 2:6, 533-536
CrossRef74
Peter Leone, Terri Warren, Kamal Hamed, Kenneth Fife, Anna Wald. (2007) Famciclovir Reduces Viral Mucosal Shedding in HSV-Seropositive Persons. Sexually Transmitted Diseases 34:11, 900-907
CrossRef75
Elisabetta Miserocchi, Giulio Modorati, Laura Galli, Paolo Rama. (2007) Efficacy of Valacyclovir vs Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease: A Pilot Study. American Journal of Ophthalmology 144:4, 547-551.e1
CrossRef76
Alejandra Varela, Anita Arora, Natalia Mendoza, Daniel Carrasco, Stephen Tyring. (2007) Famciclovir for recurrent genital herpes. Expert Review of Obstetrics & Gynecology 2:5, 557-563
CrossRef77
Julie Richards, Delia Scholes, Selin Caka, Linda Drolette, Amalia Meier Magaret, Patty Yarbro, William Lafferty, Richard Crosby, Ralph Diclemente, Anna Wald. (2007) HSV-2 Serologic Testing in an HMO Population: Uptake and Psychosocial Sequelae. Sexually Transmitted Diseases 34:9, 718-725
CrossRef78
Nicolas Nagot, Sinead Delany-Moretlwe, Philippe Mayaud. (2007) Antiherpetic therapy for HIV infection: linking prevention and care. Future HIV Therapy 1:2, 131-136
CrossRef79
Scott T Rottinghaus, Richard J Whitley. (2007) Current non-AIDS antiviral chemotherapy. Expert Review of Anti-infective Therapy 5:2, 217-230
CrossRef80
Juan Jorge Manriquez, Maria Francisca Villouta, Hywel C. Williams. (2007) Evidence-based dermatology: Number needed to treat and its relation to other risk measures. Journal of the American Academy of Dermatology 56:4, 664-671
CrossRef81
John R. Williams, Jamie C. Jordan, E Anne Davis, Geoffrey P. Garnett. (2007) Suppressive Valacyclovir Therapy: Impact on the Population Spread of HSV-2 Infection. Sexually Transmitted Diseases 34:3, 123-131
CrossRef82
Nagot, Nicolas, Ouédraogo, Abdoulaye, Foulongne, Vincent, Konaté, Issouf, Weiss, Helen A., Vergne, Laurence, Defer, Marie-Christine, Djagbaré, Didier, Sanon, Anselme, Andonaba, Jean-Baptiste, Becquart, Pierre, Segondy, Michel, Vallo, Roselyne, Sawadogo, Adrien, Van de Perre, Philippe, Mayaud, Philippe, . (2007) Reduction of HIV-1 RNA Levels with Therapy to Suppress Herpes Simplex Virus. New England Journal of Medicine 356:8, 790-799
Full Text83
S. Samraj, R. Patel. (2007) The clinical management of genital herpes. European Clinics in Obstetrics and Gynaecology 2:4, 191-196
CrossRef84
Anders Strand. (2007) Diagnosis of genital herpes: the role and place of HSV testing in clinical practice. European Clinics in Obstetrics and Gynaecology 2:4, 181-189
CrossRef85
Adriana Weinberg, Jeffry J. Leary, Robert T. Sarisky, Myron J. Levin. (2007) Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. Journal of Clinical Virology 38:2, 139-145
CrossRef86
Dean Follmann, Ann Duerr, Stephen Tabet, Peter Gilbert, Zoe Moodie, Patricia Fast, Massimo Cardinali, Steve Self. (2007) Endpoints and Regulatory Issues in HIV Vaccine Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:1, 49-60
CrossRef87
Aaron B. Caughey, Adam C. Urato. (2007) Financial relationships between research and pharmaceutical/biotech companies: disclosure is imperative. American Journal of Obstetrics and Gynecology 196:1, e13
CrossRef88
C. Deback, J.-M. Huraux. (2007) Vaccination antiherpès simplex virus: perspectives. La Revue de Médecine Interne 28:1, 16-21
CrossRef89
Guy Boivin, Nathalie Goyette, Yan Sergerie, Sharon Keays, Tristan Booth. (2006) Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis. Journal of Clinical Virology 37:4, 248-251
CrossRef90
Ernst R. Berndt, Iain M. Cockburn, Karen A. Grepin. (2006) The Impact of Incremental Innovation in Biopharmaceuticals. Pharmacoeconomics 24:Supplement 2, 69???86
CrossRef91
Nicola Low, Nathalie Broutet, Yaw Adu-Sarkodie, Pelham Barton, Mazeda Hossain, Sarah Hawkes. (2006) Global control of sexually transmitted infections. The Lancet 368:9551, 2001-2016
CrossRef92
Stephen Tyring, Gary Richwald, Kamal Hamed. (2006) Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes. Archives of Gynecology and Obstetrics 275:1, 1-3
CrossRef93
Marwan Shalabi, Richard J. Whitley. (2006) Clinical Practice: Recurrent Benign Lymphocytic Meningitis. Clinical Infectious Diseases 43:9, 1194-1197
CrossRef94
Donald C Vinh, Fred Y Aoki. (2006) Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opinion on Pharmacotherapy 7:16, 2271-2286
CrossRef95
Alan T. N. Tita, William A. Grobman, Dwight J. Rouse. (2006) Antenatal Herpes Serologic Screening. Obstetrics & Gynecology 108:5, 1247-1253
CrossRef96
H Hunter Handsfield, Terri Warren, Mica Werner, James A. Phillips. (2006) Suppressive Therapy With Valacyclovir in Early Genital Herpes: A Pilot Study of Clinical Efficacy and Herpes-Related Quality of Life. Sexually Transmitted Diseases PAP,
CrossRef97
K. H. Fife, T. J. Warren, R. D. Ferrera, D. G. Young, S. E. Justus, C. K. Heitman, S. M. Burroughs. (2006) Effect of Valacyclovir on Viral Shedding in Immunocompetent Patients With Recurrent Herpes Simplex Virus 2 Genital Herpes: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Mayo Clinic Proceedings 81:10, 1321-1327
CrossRef98
Adam C Urato, Aaron B Caughey. (2006) Universal prenatal herpes screening is a bad idea in pregnancy. The Lancet 368:9539, 898-899
CrossRef99
Anna Wald, Stacy Selke, Terri Warren, Fred Y. Aoki, Stephen Sacks, Francisco Diaz-Mitoma, Lawrence Corey. (2006) Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding. Sexually Transmitted Diseases 33:9, 529-533
CrossRef100
Claire Ryan, George Kinghorn. (2006) Clinical assessment of assays for diagnosis of herpes simplex infection. Expert Review of Molecular Diagnostics 6:5, 767-775
CrossRef101
Viviana Simon, David D Ho, Quarraisha Abdool Karim. (2006) HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. The Lancet 368:9534, 489-504
CrossRef102
Jeanne S. Sheffield, James B. Hill, Lisa M. Hollier, Vanessa R. Laibl, Scott W. Roberts, Pablo J. Sanchez, George D. Wendel. (2006) Valacyclovir Prophylaxis to Prevent Recurrent Herpes at Delivery. Obstetrics & Gynecology 108:1, 141-147
CrossRef103
Richard Whitley, Francisco Diaz-Mitoma, Kamal Hamed. (2006) Single-day famciclovir therapy for recurrent genital herpes. Current Medical Research and Opinion 22:7, 1307-1310
CrossRef104
Julie S Brantley, Lindsey Hicks, Karan Sra, Stephen K Tyring. (2006) Valacyclovir for the treatment of genital herpes. Expert Review of Anti-infective Therapy 4:3, 367-376
CrossRef105
R. Morrow, D. Friedrich. (2006) Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clinical Microbiology and Infection 12:5, 463-469
CrossRef106
Rachna Gupta, Anna Wald. (2006) Genital herpes: antiviral therapy for symptom relief and prevention of transmission. Expert Opinion on Pharmacotherapy 7:6, 665-675
CrossRef107
William W. Andrews, Debora F. Kimberlin, Richard Whitley, Suzanne Cliver, Patrick S. Ramsey, Robert Deeter. (2006) Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. American Journal of Obstetrics and Gynecology 194:3, 774-781
CrossRef108
R. Marculescu, L. Richter, K. Rappersberger. (2006) Infektionen mit Herpes-simplex- und Varicella-zoster-Viren in der Schwangerschaft. Der Hautarzt 57:3, 207-216
CrossRef109
Betty A. Donoval, Douglas J. Passaro, Jeffrey D. Klausner. (2006) The Public Health Imperative for a Neonatal Herpes Simplex Virus Infection Surveillance System. Sexually Transmitted Diseases 33:3, 170-174
CrossRef110
Rebecca Pellett Madan, Marla J Keller, Betsy C Herold. (2006) Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Current Opinion in Infectious Diseases 19:1, 49-54
CrossRef111
Michael F. Rein. (2006) Should sexually transmitted disease clinics routinely offer serologic testing for genital herpes?. Current Infectious Disease Reports 8:1, 1-2
CrossRef112
Karen E. Mark, H. Nina Kim, Anna Wald, Carolyn Gardella, Susan D. Reed. (2006) Targeted prenatal herpes simplex virus testing: Can we identify women at risk of transmission to the neonate?. American Journal of Obstetrics and Gynecology 194:2, 408-414
CrossRef113
Erik De Clercq, Hugh J Field. (2006) Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology 147:1, 1-11
CrossRef114
Darren B. Russell. (2006) Herpes and HIV infection—has the time come to act?. Sexual Health 3:2, 67
CrossRef115
Esther E Freeman, Helen A Weiss, Judith R Glynn, Pamela L Cross, James A Whitworth, Richard J Hayes. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:1, 73-83
CrossRef116
F. Y. Aoki, S. Tyring, F. Diaz-Mitoma, G. Gross, J. Gao, K. Hamed. (2006) Single-Day, Patient-Initiated Famciclovir Therapy for Recurrent Genital Herpes: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases 42:1, 8-13
CrossRef117
David A. Baker. (2005) Risk factors for herpes simplex virus transmission to pregnant women: A couples study. American Journal of Obstetrics and Gynecology 193:6, 1887-1888
CrossRef118
Marc Steben. (2005) Genital Herpes Simplex Virus Infection. Clinical Obstetrics and Gynecology 48:4, 838-844
CrossRef119
Carolyn Gardella, Zane Brown, Anna Wald, Stacy Selke, Judy Zeh, Rhoda Ashley Morrow, Lawrence Corey. (2005) Risk factors for herpes simplex virus transmission to pregnant women: A couples study. American Journal of Obstetrics and Gynecology 193:6, 1891-1899
CrossRef120
David A Baker. (2005) New management of the pregnant patient to reduce the risk of transmitting herpes to the newborn. Expert Review of Pharmacoeconomics & Outcomes Research 5:6, 783-790
CrossRef121
Rumi Sato, Mitsuyoshi Ayabe, Hiroshi Shoji, Takashi Ichiyama, Yumiko Saito, Ryo Hondo, Yoshito Eizuru. (2005) Herpes simplex virus type 2 recurrent meningitis (Mollaret's meningitis): a consideration for the recurrent pathogenesis. Journal of Infection 51:4, e217-e220
CrossRef122
Mark N. Prichard, Ravi Kaiwar, Winthrop T. Jackman, Debra C. Quenelle, Deborah J. Collins, Earl R. Kern, George M. Kemble, Richard R. Spaete. (2005) Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23:46-47, 5424-5431
CrossRef123
S. L. Sacks, F. Y. Aoki, A. Y. Martel, S. D. Shafran, M. Lassonde. (2005) Clinic-Initiated, Twice-Daily Oral Famciclovir for Treatment of Recurrent Genital Herpes: A Randomized, Double-Blind, Controlled Trial. Clinical Infectious Diseases 41:8, 1097-1104
CrossRef124
Raj Patel. (2005) Genital herpes. Medicine 33:10, 55-58
CrossRef125
Peter Leone. (2005) Reducing the risk of transmitting genital herpes: advances in understanding and therapy. Current Medical Research and Opinion 21:10, 1577-1582
CrossRef126
Zane A. Brown, Carolyn Gardella, Anna Wald, Rhoda Ashley Morrow, Lawrence Corey. (2005) Genital Herpes Complicating Pregnancy. Obstetrics & Gynecology 106:4, 845-856
CrossRef127
Kelika A. Konda, Jeffrey D. Klausner, Andres G. Lescano, Segundo Leon, Franca R. Jones, Jose Pajuelo, Carlos F. Caceres, Thomas J. Coates. (2005) The Epidemiology of Herpes Simplex Virus Type 2 Infection in Low-Income Urban Populations in Coastal Peru. Sexually Transmitted Diseases 32:9, 534-541
CrossRef128
Carolyn Gardella, Zane A. Brown, Anna Wald, Rhoda Ashley Morrow, Stacy Selke, Elizabeth Krantz, Lawrence Corey. (2005) Poor Correlation Between Genital Lesions and Detection of Herpes Simplex Virus in Women in Labor. Obstetrics & Gynecology 106:2, 268-274
CrossRef129
David A Baker. (2005) Antiviral therapy for genital herpes infections in pregnancy. Expert Review of Anti-infective Therapy 3:3, 385-392
CrossRef130
Steven J. Reynolds, Thomas C. Quinn. (2005) Developments in STD/HIV Interactions: The Intertwining Epidemics of HIV and HSV-2. Infectious Disease Clinics of North America 19:2, 415-425
CrossRef131
Raj Patel, Anne Rompalo. (2005) Managing Patients with Genital Herpes and their Sexual Partners. Infectious Disease Clinics of North America 19:2, 427-438
CrossRef132
Terri Warren, Charles Ebel. (2005) Counseling the Patient who has Genital Herpes or Genital Human Papillomavirus Infection. Infectious Disease Clinics of North America 19:2, 459-476
CrossRef133
T. L. Cherpes, M. A. Melan, J. A. Kant, L. A. Cosentino, L. A. Meyn, S. L. Hillier. (2005) Genital Tract Shedding of Herpes Simplex Virus Type 2 in Women: Effects of Hormonal Contraception, Bacterial Vaginosis, and Vaginal Group B Streptococcus Colonization. Clinical Infectious Diseases 40:10, 1422-1428
CrossRef134
P GRIFFITHS. (2005) Herpesviruses. Medicine 33:5, 122-125
CrossRef135
Rashida K. Rana, Jeanne M. Pimenta, Daniel M. Rosenberg, Stephen K. Tyring, Jorma Paavonen, Suzanne F. Cook, Noah J. Robinson. (2005) Demographic, Behavioral, and Knowledge Factors Associated With Herpes Simplex Virus Type 2 Infection Among Men Whose Current Female Partner Has Genital Herpes. Sexually Transmitted Diseases 32:5, 308-313
CrossRef136
Bryan M. Gebhardt, Emily D. Varnell, Herbert E. Kaufman. (2005) Inhibition of Cyclooxygenase 2 Synthesis Suppresses Herpes simplex Virus Type 1 Reactivation. Journal of Ocular Pharmacology and Therapeutics 21:2, 114-120
CrossRef137
Jeanne M. Marrazzo. (2005) Sexual tourism: implications for travelers and the destination culture. Infectious Disease Clinics of North America 19:1, 103-120
CrossRef138
Gerald Kleymann. (2005) Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opinion on Investigational Drugs 14:2, 135-161
CrossRef139
Danielle C Newton, Marita P McCabe. (2005) The impact of stigma on couples managing a sexually transmitted infection. Sexual and Relationship Therapy 20:1, 51-63
CrossRef140
Lisa E. Manhart, King K. Holmes. (2005) Randomized Controlled Trials of Individual‐Level, Population‐Level, and Multilevel Interventions for Preventing Sexually Transmitted Infections: What Has Worked?. The Journal of Infectious Diseases 191:s1, S7-S24
CrossRef141
Connie L. Celum, Noah J. Robinson, Myron S. Cohen. (2005) Potential Effect of HIV Type 1 Antiretroviral and Herpes Simplex Virus Type 2 Antiviral Therapy on Transmission and Acquisition of HIV Type 1 Infection. The Journal of Infectious Diseases 191:s1, S107-S114
CrossRef142
Barbara Suligoi, Theresa M. Wagner, Massimo Ciccozzi, Giovanni Rezza. (2005) The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies. Vaccine 23:12, 1437-1445
CrossRef143
Yvonne Gilleece, Ann Sullivan. (2005) Management of sexually transmitted infections in HIV positive individuals. Current Opinion in Infectious Diseases 18:1, 43-47
CrossRef144
S. L. Guerry, H. M. Bauer, J. D. Klausner, B. Branagan, P. R. Kerndt, B. G. Allen, G. Bolan. (2005) Recommendations for the Selective Use of Herpes Simplex Virus Type 2 Serological Tests. Clinical Infectious Diseases 40:1, 38-45
CrossRef145
Arun Chakrabarty, Karl Beutner. (2004) Therapy of other viral infections: herpes to hepatitis. Dermatologic Therapy 17:6, 465-490
CrossRef146
David Baker, Zane Brown, Lisa M. Hollier, George D. Wendel, Lisa Hulme, Dorothea A. Griffiths, Josephine Mauskopf. (2004) Cost-effectiveness of herpes simplex virus type 2 serologic testing and antiviral therapy in pregnancy. American Journal of Obstetrics and Gynecology 191:6, 2074-2084
CrossRef147
J Dennis Fortenberry, Gregory D. Zimet, Rebecca Brady, Jingwei Wu, Wanzhu Tu, Katherine M. Stone, Susan L. Rosenthal, David I. Bernstein, Kenneth H. Fife. (2004) Return for Results After Herpes Simplex Virus Type 2 Screening. Sexually Transmitted Diseases 31:11, 655-658
CrossRef148
Gregory D. Zimet, Susan L. Rosenthal, J Dennis Fortenberry, Rebecca C. Brady, Wanzhu Tu, Jingwei Wu, David I. Bernstein, Lawrence R. Stanberry, Katherine M. Stone, Jami S. Leichliter, Kenneth H. Fife. (2004) Factors Predicting the Acceptance of Herpes Simplex Virus Type 2 Antibody Testing Among Adolescents and Young Adults. Sexually Transmitted Diseases 31:11, 665-669
CrossRef149
Arun Chakrabarty, Katie R Pang, Jashin J Wu, Julio Narvaez, Michael Rauser, David B Huang, Karl R Beutner, Stephen K Tyring. (2004) Emerging therapies for herpes viral infections (types 1 – 8). Expert Opinion on Emerging Drugs 9:2, 237-256
CrossRef150
Sally Blower, Li Ma. (2004) Calculating the Contribution of Herpes Simplex Virus Type 2 Epidemics to Increasing HIV Incidence: Treatment Implications. Clinical Infectious Diseases 39:s5, S240-S247
CrossRef151
John G. Bartlett. (2004) Recent Developments in the Management of Herpes Simplex Virus Infection in HIV‐Infected Persons. Clinical Infectious Diseases 39:s5, S237-S239
CrossRef152
L Hollier, GD Wendel, Lisa Hollier. 2004. Third trimester antiviral therapy for preventing recurrent genital herpes at delivery. .
CrossRef153
A. Vermes. (2004) Valaciclovir voorkomt overdracht van herpes simplex. MFM 42:9, 249-250
CrossRef154
Tomio Miyai, Katherine R. Turner, Charlotte K. Kent, Jeffrey Klausner. (2004) The Psychosocial Impact of Testing Individuals with No History of Genital Herpes for Herpes Simplex Virus Type 2. Sexually Transmitted Diseases 31:9, 517-521
CrossRef155
Rhoda Ashley Morrow, David Friedrich, Elizabeth Krantz, Anna Wald. (2004) Development and Use of a Type-Specific Antibody Avidity Test Based on Herpes Simplex Virus Type 2 Glycoprotein G. Sexually Transmitted Diseases 31:8, 508-515
CrossRef156
Kathleen A Stellrecht. (2004) Nucleic acid amplification technology for the diagnosis of genital herpes infection. Expert Review of Molecular Diagnostics 4:4, 485-493
CrossRef157
Lara Strick, Anna Wald. (2004) Type-specific testing for herpes simplex virus. Expert Review of Molecular Diagnostics 4:4, 443-453
CrossRef158
Kimberlin, David W., Rouse, Dwight J., . (2004) Genital Herpes. New England Journal of Medicine 350:19, 1970-1977
Full Text159
. (2004) Overdracht herpes genitalis vermindert met dagelijks valaciclovir. Huisarts en Wetenschap 47:4, 731-731
CrossRef160
Lawrence Corey, Anna Wald, Connie L. Celum, Thomas C. Quinn. (2004) The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics. JAIDS Journal of Acquired Immune Deficiency Syndromes 35:5, 435-445
CrossRef161
Diane R. Blake. (2004) Adolescent sexually transmitted diseases: Recent developments. Current Infectious Disease Reports 6:2, 141-148
CrossRef162
W. I. Meijden. (2004) Herpes labialis en genitalis. Bijblijven 20:3, 93-98
CrossRef163
Basil Donovan. (2004) Sexually transmissible infections other than HIV. The Lancet 363:9408, 545-556
CrossRef164
Crumpacker, Clyde S., . (2004) Use of Antiviral Drugs to Prevent Herpesvirus Transmission. New England Journal of Medicine 350:1, 67-68
Full Text165
David M. Cocchetto. (2004) Regulatory Decision‐Making in the United States Based on a Single Pivotal Clinical Study: Principles and Precedents. Clinical Research and Regulatory Affairs 21:2, 101-143
CrossRef
